This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Boston Scientific Schedule Of Major Events And Presentations At EuroPCR 2013

NATICK, Mass., May 17, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) is scheduled to participate at the annual EuroPCR Scientific Program May 21-24 in Paris.

"We are pleased to present a particularly rich and diversified set of data this year at EuroPCR," said Keith Dawkins, M.D., global chief medical officer, Boston Scientific.  "The primary endpoint results for several trials will be presented, including the NG PROMUS trial, which evaluated our Promus PREMIER Stent System and the EVOLVE study two-year results, which evaluated the SYNERGY Stent System.  We believe the results will reinforce our commitment to maintaining a leadership position in the worldwide drug-eluting stent market.  We also look forward to sharing results from the REDUCE-HTN study which is evaluating our Vessix Renal Denervation System, a uniquely differentiated technology that offers the precision of bipolar energy delivery.  In the structural heart area, we will present data from our REPRISE I and II trials which evaluate the Lotus Aortic Valve System designed to reduce paravalvular leakage.  Finally, the set of data presented at EuroPCR includes a series of presentations on our WATCHMAN Left Atrial Appendage Closure device, the most clinically studied technology of its kind." 

Schedule of Events  All events are Paris time and take place at the Palais des Congres.

Tuesday, May 21   PE PROVE Post-Approval Trial Results Results from the multicenter PROMUS Element™ European Post-Approval Surveillance Trial (PE PROVE) will be presented.  The session will showcase one-year outcomes in 1,010 all-comer patients treated with the PROMUS Element Everolimus-Eluting Stent System.  The session will be held from 1:36p.m. to 1:43 p.m. in room 243.  Speaker: R. Moreno.

Wednesday, May 22   NG PROMUS Trial Results   The first-in-human results will be presented as a late-breaking clinical trial titled, "Clinical, Angiographic and Intravascular Ultrasound Outcomes of the NG PROMUS Clinical Study Evaluating the Novel Promus PREMIER Everolimus–Eluting Platinum Chromium Stent System."  The session will be held from 9:45a.m. to 11:45a.m. in room 243.  Speaker: J. Ormiston.

EVOLVE Trial Results Two-year clinical outcomes of the EVOLVE study will be presented as a late-breaking clinical trial from 2:10p.m. to 3:10p.m. in room 242AB.  Speaker: I. Meredith.

Boston Scientific Symposium Featuring The SYNERGY Stent  Boston Scientific will host a symposium on its SYNERGY Stent technology featuring a novel bioabsorbable polymer coating.  The session, chaired by I. Meredith, is named "Synchronizing polymer absorption and drug elution with the SYNERGY Stent: Implications for healing and dual antiplatelet therapy duration."  The session aims to discuss the impact of the polymer on healing, and current evidence when assessing ischemic bleeding and thrombotic risks for specific patient subsets.  The symposium will be held from 12:00p.m. to 1:00p.m. in room 251.  Speakers: J. Escaned, T. Cuisset and K. Dawkins.  

REPRISE I and II Trial Results  Two presentations will feature data from the clinical program studying the Lotus Valve System:  

  • REPRISE I

One-year outcomes of the REPRISE I feasibility study will be shared during an oral presentation from 11:09a.m. to 11:17a.m. in room 351.  Speaker: I. Meredith.

  • REPRISE II

Results of the evaluation of safety and performance of the Lotus Valve System will be presented as a late-breaking clinical trial.  The session is named, "Repositionable percutaneous replacement of a stenotic aortic valve through implantation of the Lotus Valve System: 30-day outcomes for the first 60 patients."  The presentation is scheduled from 3:40p.m. to 4:40p.m. in room 241.  Speaker: I. Meredith.

Boston Scientific Symposium Featuring REDUCE- HTN Clinical Trial Results     Boston Scientific will host a symposium titled, "Catheter-Based Renal Sympathetic Denervation, Building Momentum with the Next Generation Vessix Renal Denervation System."  The symposium will be co-moderated by T.F. Luscher and F. Mahfoud, and will include presentations on the state of catheter-based renal denervation, as well an update on the REDUCE-HTN trial, a post-market surveillance study designed to evaluate the Vessix Renal Denervation System.  The symposium will be held from 4:45p.m. to 6:15p.m. in room 242AB.  Speakers: M. Mazor, J. Schofer, E. Wyffels and G. Grassi.

Thursday, May 23   Boston Scientific Symposium Featuring Left Atrial Appendage Closure For Stroke Prevention  Boston Scientific is scheduled to host a symposium titled, "Left atrial appendage closure for stroke prevention: What every interventional cardiologist should know."  The session will be chaired by M.W Bergman.  Objectives of the session are to understand the new evidence for left atrial appendage closure including the PREVAIL trial results which evaluated the Boston Scientific WATCHMAN Left Atrial Appendage Closure Device, to define patient selection and access for left atrial appendage closure and to discuss the role of left atrial appendage closure versus anticoagulation for reducing risk of stroke in atrial fibrillation especially in patients with comorbidities requiring antithrombotic therapy.  The symposium is scheduled to occur from 12:00p.m. to 1:00p.m. in the Maillot room.  Speakers: D. Holmes, R. Virmani and C. K. Naber.

Boston Scientific Symposium Featuring Chronic Total Occlusion Boston Scientific is scheduled to host a symposium titled, "Contemporary coronary chronic total occlusion PCI:  Integrating the hybrid approach to your practice."  The session will be hosted by T. De Martini and S. Walsh.  The session aims to demonstrate how tailoring coronary chronic total occlusion (CTO) crossing strategies to anatomical and morphologic characteristics can increase success, and will discuss the role of the Boston Scientific CrossBoss™ and Stingray™ Crossing and Re-entry Devices in CTO PCI.   The symposium is scheduled to occur from 4:45p.m. to 6:15p.m. in Theatre Havane.  Speakers: M. Carlino, S. Rinfret, J. Spratt and C. Hanratty.



Stock quotes in this article: BSX 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs